Language:

Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer

Nature medicine, 2019-03, Vol.25 (3), p.403-418 [Peer Reviewed Journal]

COPYRIGHT 2019 Nature Publishing Group ;COPYRIGHT 2019 Nature Publishing Group ;2019© Springer Nature America, Inc. 2019 ;ISSN: 1078-8956 ;EISSN: 1546-170X ;DOI: 10.1038/s41591-019-0376-8 ;PMID: 30842676

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer
Author: Mohammad, Helai P ; Barbash, Olena ; Creasy, Caretha L
Subjects: Abiraterone ; Antimitotic agents ; Antineoplastic agents ; Antineoplastic Agents - therapeutic use ; Atezolizumab ; Cancer ; Cancer treatment ; Carboplatin ; Care and treatment ; Clinical trials ; Daratumumab ; Decitabine ; DNA (Cytosine-5-)-Methyltransferases - antagonists & inhibitors ; Drug development ; Drug Discovery ; Drugs ; Enzalutamide ; Enzyme Inhibitors - therapeutic use ; Epigenesis, Genetic ; Epigenetic inheritance ; Epigenetics ; Fulvestrant ; Health aspects ; Histone Acetyltransferases - antagonists & inhibitors ; Histone Deacetylase Inhibitors - therapeutic use ; Histone-Lysine N-Methyltransferase - antagonists & inhibitors ; Humans ; Ipilimumab ; Modulators ; Molecular Targeted Therapy ; Neoplasms - drug therapy ; Neoplasms - genetics ; Protein-Arginine N-Methyltransferases - therapeutic use ; Proteins ; Ruxolitinib ; Therapeutics
Is Part Of: Nature medicine, 2019-03, Vol.25 (3), p.403-418
Description: Epigenetic dysregulation is a common feature of most cancers, often occurring directly through alteration of epigenetic machinery. Over the last several years, a new generation of drugs directed at epigenetic modulators have entered clinical development, and results from these trials are now being disclosed. Unlike first-generation epigenetic therapies, these new agents are selective, and many are targeted to proteins which are mutated or translocated in cancer. This review will provide a summary of the epigenetic modulatory agents currently in clinical development and discuss the opportunities and challenges in their development. As these drugs advance in the clinic, drug discovery has continued with a focus on both novel and existing epigenetic targets. We will provide an overview of these efforts and the strategies being employed.
Publisher: United States: Nature Publishing Group
Language: English
Identifier: ISSN: 1078-8956
EISSN: 1546-170X
DOI: 10.1038/s41591-019-0376-8
PMID: 30842676
Source: AUTh Library subscriptions: ProQuest Central
MEDLINE

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer

COPYRIGHT 2019 Nature Publishing Group ;COPYRIGHT 2019 Nature Publishing Group ;2019© Springer Nature America, Inc. 2019 ;ISSN: 1078-8956 ;EISSN: 1546-170X ;DOI: 10.1038/s41591-019-0376-8 ;PMID: 30842676

Searching Remote Databases, Please Wait